Axxcess Wealth Management LLC Trims Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Axxcess Wealth Management LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 0.8% during the 4th quarter, Holdings Channel reports. The institutional investor owned 97,230 shares of the company’s stock after selling 818 shares during the period. Axxcess Wealth Management LLC’s holdings in Johnson & Johnson were worth $14,061,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of JNJ. Swedbank AB grew its position in shares of Johnson & Johnson by 5.3% during the third quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock worth $358,980,000 after buying an additional 111,570 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of Johnson & Johnson by 10.5% during the third quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock worth $562,723,000 after buying an additional 329,473 shares in the last quarter. United Bank lifted its stake in Johnson & Johnson by 5.6% during the third quarter. United Bank now owns 3,788 shares of the company’s stock worth $614,000 after purchasing an additional 202 shares during the last quarter. Clarkston Capital Partners LLC lifted its stake in Johnson & Johnson by 1.3% during the third quarter. Clarkston Capital Partners LLC now owns 123,157 shares of the company’s stock worth $19,959,000 after purchasing an additional 1,632 shares during the last quarter. Finally, TrinityPoint Wealth LLC lifted its stake in Johnson & Johnson by 0.6% during the third quarter. TrinityPoint Wealth LLC now owns 46,994 shares of the company’s stock worth $7,616,000 after purchasing an additional 295 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on JNJ shares. Wells Fargo & Company decreased their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Raymond James reduced their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Leerink Partners reduced their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Monday, March 10th. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Stock Up 0.1 %

Johnson & Johnson stock opened at $162.94 on Tuesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The firm has a market capitalization of $392.66 billion, a price-to-earnings ratio of 24.50, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The stock’s fifty day moving average is $155.37 and its two-hundred day moving average is $156.26.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Johnson & Johnson’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.29 earnings per share. Analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.04%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.